No Enhance-ment From Zetia

Results from the trial whose seemingly endless duration sparked a Congressional probe are finally in. The findings of the Enhance trial were far from what Merck (NYSE: MRK  ) and Schering-Plough (NYSE: SGP  )  -- the companies that market Vytorin -- were hoping for.

The good news was that Vytorin, which is a combination of Zetia and Zocor, lowered low-density lipoprotein (LDL) cholesterol -- that's the bad kind -- more than Zocor alone. That's not a big surprise, since previous clinical trials have shown that Zetia works well in combination and by itself. The previous trials are the reason Zetia and Vytorin have both become multibillion-dollar drugs.

The bad news was that the lowered cholesterol didn't translate into less plaque in the arteries. Vytorin and Zocor caused a change in thickness of the arteries that was statistically the same after two years of use.

In clinical trials, the same is often good enough, but the problem for the cholesterol-fighting duo is that Zocor is available as a much cheaper generic. Doctors may be inclined to prescribe generic statins in order to save their patients some money. That's something that competing statins such as Pfizer's (NYSE: PFE  ) Lipitor and AstraZeneca's (NYSE: AZN  ) Crestor have been trying to fight, and its one of the reasons my Foolish colleague picked Pfizer as the worst stock of 2008.

Of course, patients -- and their doctors, for that matter -- don't care about the thickness of arteries. Ultimately all they care about is whether the drugs will make them live longer. To that end, Merck and Schering are testing Vytorin in three large trials involving more than 20,000 patients, to test the drug's abilities to lower heart attacks and other cardiac events. Ultimately, Zetia's and Vytorin's futures depends on those trials.

More cholesterol-lowering Foolishness:


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 558228, ~/Articles/ArticleHandler.aspx, 7/26/2014 12:30:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASD 4,449.56 -22.54 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/25/2014 4:03 PM
MRK $58.15 Down -0.06 -0.10%
Merck & Co., Inc. CAPS Rating: ***
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****
AZN $74.48 Down -0.04 -0.05%
AstraZeneca plc (A… CAPS Rating: ***
PFE $30.19 Down -0.15 -0.49%
Pfizer CAPS Rating: ****

Advertisement